McIntosh M E, Smith W G, Junor B J, Forrest G, Brodie M J
Eur J Clin Pharmacol. 1985;28(2):187-91. doi: 10.1007/BF00609690.
The distribution of cefuroxime (250 mg) was studied in patients with renal failure undergoing continuous ambulatory peritoneal dialysis (CAPD). 10 uninfected patients received the drug intravenously and intraperitoneally, while 9 patients with peritonitis were randomly allocated to intravenous or intraperitoneal administration. Samples were taken over the first 6 hour dialysis period. In the infected patients, more drug (p less than 0.01) crossed into the peritoneal cavity following intravenous injection and reached the systemic circulation following intraperitoneal administration than in the uninfected group. This increased permeability of the peritoneal membrane during infection may result in unexpected systemic toxicity in patients treated with intraperitoneal antibiotics.
对接受持续性非卧床腹膜透析（CAPD）的肾衰竭患者进行了头孢呋辛（250毫克）分布情况的研究。10名未感染患者接受了静脉和腹腔内给药，而9名腹膜炎患者被随机分配接受静脉或腹腔内给药。在透析的前6小时内采集样本。在感染患者中，静脉注射后进入腹腔的药物更多（p小于0.01），腹腔给药后进入体循环的药物也比未感染组多。感染期间腹膜通透性的增加可能导致接受腹腔内抗生素治疗的患者出现意外的全身毒性。
